NCT02965950
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: TP53
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: TP53 tumor mutation is not required
Exclusions: Patients with HER2+ metastatic breast cancer in the first line setting
https://ClinicalTrials.gov/show/NCT02965950